Draft medication scaffold. Needs source pass before publish.
Sections
Clomipramine is one of those drugs psychiatry quietly respects while also being relieved it doesn’t have to start with it anymore. For obsessive-compulsive disorder, clomipramine is a real medication with real bite. It helped define modern OCD pharmacology. The reason it isn’t the routine first move now isn’t that it stopped working. It’s that the SSRIs do similar work with less tricyclic baggage attached.
So clomipramine lives in that interesting second-line space. Strong drug. Legit OCD medication. Sometimes very worth using. Also dry mouth, constipation, sweating, sedation, sexual side effects, orthostasis, and enough cardiac and overdose concern that nobody should pretend it’s as casual as sertraline. That’s the real profile.
What it actually does
Clomipramine is a tricyclic antidepressant, but unlike the older tricyclics people mostly remember for depression, its clinical identity is tied to serotonin reuptake inhibition strongly enough that OCD is where it built its reputation. That’s the reason you’ll still hear it mentioned with a little respect in OCD conversations. It was there before the SSRIs took over the first-line slot.
In the adult OCD treatment literature, clomipramine remains one of the more effective medication options. It isn’t the whole story, because exposure and response prevention therapy is still the heavyweight treatment in OCD, but if we’re talking drugs, clomipramine is not an afterthought.
Where it tends to help most
The classic use-case is obsessive-compulsive disorder that hasn’t moved enough on SSRIs or where the clinician wants a medication with a little more force behind it. Intrusive thoughts. Compulsions. Mental rituals. The whole ugly stuck-loop quality of OCD. Clomipramine can help there, and it can help a lot.
It also has an off-label sexual-medicine life because low-dose clomipramine can delay ejaculation. That use is real, though it doesn’t cancel out the rest of the drug’s side-effect burden and it doesn’t make clomipramine some smooth lifestyle medication. It’s still a TCA with all the TCA baggage that implies.
There’s also the usual antidepressant caution around activation, mania in bipolar vulnerability, and the long taper question. Clomipramine is not a forgiving drug to stop abruptly, and the taper question deserves a real plan.
When it makes sense and when it doesn’t
I reach for clomipramine when OCD is the real problem, the patient has already had honest SSRI treatment or needs a stronger medication conversation, and they’re willing to tolerate a less elegant side-effect profile in exchange for a potentially stronger push on symptoms. I also take it seriously in the patient with OCD plus premature ejaculation where one drug plausibly helps both, assuming the rest of the medical picture makes sense.
- What symptom or function is supposed to change, not just whether the medication feels noticeable.
- Sleep, appetite, libido, mood, anxiety, blood pressure, sedation, and any side effect that changes the trade.
- Missed doses, alcohol, cannabis, and other meds, because those can make a clean read impossible.
The useful question with Clomipramine (Anafranil) is not whether it sounds strong or old or scary. The useful question is whether the benefit is real enough to justify the trade.
I don’t reach for it casually in somebody who has cardiac risk, major constipation, urinary retention issues, severe side-effect sensitivity, or a high overdose concern. And I don’t use it as an excuse to dodge ERP therapy. Clomipramine can absolutely help OCD, but the medication-only version of OCD treatment is usually the incomplete version.
The patient-autonomy part
If somebody with stubborn OCD hears the trade and says yes to clomipramine, that’s often a reasonable decision. Especially when they’ve already bounced off two SSRIs and are tired of being told to just keep trying cleaner drugs forever. There is a point where cleaner and milder stops being the right priority.
If they hear the same trade and say no because the side-effect profile sounds miserable, also reasonable. Adults are allowed to prefer a slightly less effective but more livable medication. My job is to explain the trade honestly, including the part where clomipramine is a serious drug and not some quaint older relic.
What to know before stopping or switching
Don’t stop clomipramine cold unless there’s a clear reason to do it. You can get discontinuation symptoms, rebound anxiety, sleep disruption, and a fast return of the OCD pressure you were trying to treat in the first place. If it isn’t working or isn’t tolerable, taper and switch with a plan.
If you stay on it, pay attention to bowel function, dizziness, heart symptoms, and sexual side effects, because those are the things patients often live with quietly until they finally get sick of the medication and disappear. The right time to talk about the trade is before that happens, not after.
Bottom line
Clomipramine is one of the stronger OCD medications on the shelf and still absolutely relevant when SSRIs haven’t been enough. The reason it isn’t first-line anymore is tolerability, not lack of efficacy. The honest version is simple: for OCD, clomipramine can be very good, and for side effects, clomipramine can be very clomipramine. Sometimes that’s still a trade worth making.
Sources
- DailyMed. CLOMIPRAMINE HYDROCHLORIDE capsule. National Library of Medicine. Accessed June 6, 2026. Official label.
- Skapinakis P, Caldwell DM, Hollingworth W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016;3(8):730-739. PMID 27318812.
- Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151-161. PMID 15625214.
- Wu PC, Hung CS, Kang YN, Wu CC. Tolerability and Optimal Therapeutic Dosage of Clomipramine for Premature Ejaculation: A Systematic Review and Meta-Analysis. Sex Med. 2021;9(1):100283. PMID 33291044.
